



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.

Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated October 29, 2018

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Granules Pharmaceuticals, Inc. completed U.S. FDA inspection.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,


Please be informed that, Granules Pharmaceuticals, Inc., the wholly-owned foreign subsidiary of the Company located at Chantilly, Virginia, USA, has completed US FDA inspection from 22nd October 2018 to 26th October 2018 with two Form 483 observations. Granules Pharmaceuticals, Inc. will respond to the observations within this week. This was a prior approval inspection, intended for the ANDAs filed by Granules Pharmaceuticals, Inc. This facility is involved in development and manufacturing of Finished Dosages.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

T. Chaitanya Tummala


**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**